Abstract #1572: Pharmacokinetics of a novel fumagillol conjugate XMT-1107 in the rat

@inproceedings{Yurkovetskiy2009AbstractP,
  title={Abstract #1572: Pharmacokinetics of a novel fumagillol conjugate XMT-1107 in the rat},
  author={Alex Yurkovetskiy and Dana Shkolny and Laura C. Akullian and Mao Yin and Laraine Meyers and Robert J. Fram and Timothy B. Lowinger},
  year={2009}
}
XMT-1107 is a novel polymer fumagillol derivative, comprised of the small molecule XMT-1191 conjugated to a 70 kDa biodegradable, hydrophilic polyacetal , poly(1-hydroxymethylethylene hydroxylmethylformal) (PHF). XMT-1191, the primary release product of XMT-1107, induces antiangiogenic activity by irreversible inhibition of methionine aminopeptidase 2 and exhibits antiproliferative activity at nanomolar concentrations in a HUVEC cell assay. The conjugated drug, XMT-1107, demonstrates… CONTINUE READING

Topics from this paper.